Study Evaluating HKI-272 in Tumors

NCT00146172 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: neratinib

Sponsor

Puma Biotechnology, Inc.